Cerenome is trading at $3.31 (-10.05%) after investors reacted to its August 14, 2026 second-quarter results.
- Q2 loss reached $9.0 million, or $1.31 per share; EPS missed consensus, while $411,000 revenue missed estimates.
- Operating loss widened to $9.1 million amid clinical and commercial investment.
- Trading is occurring during the August 17, 2026 market session; no separate announcement was identified.